Low dosage monophasic oral contraceptive use and intermittent exercise performance and metabolism in humans.
Nine untrained women using low dosage monophasic oral contraceptives (OC) performed an intermittent treadmill test on two different occasions within one pill-cycle to determine the effect of OC on performance and some commonly used metabolic markers. The first test was performed after 5-8 days of resuming the OC agents after menstrual bleeding while the other test was performed after 19-21 days. Performance time on the final exhausting run of six intermittent high intensity 20 s runs was no different between trials [mean days 5-8: 22.3 (SEM 1.2) s vs days 19-21: 22.7 (SEM 1.1) s]. There was no difference in heart rate [peak heart rate days 5-8: 183 (SEM 3) beats.min-1 vs days 19-21: 186 (SEM 2) beats.min-1], oxygen consumption during any run [run 5 of days 5-8: 1,392 (SEM 51) ml.min-1 vs run 5 of days 19-21: 1,494 (SEM 3) ml.min-1] or in any of the metabolic variables measured at any time in venous blood [peak blood lactate concentration days 5-8: 8.4 (SEM 0.3) mmol.l-1 vs days 19-21: 8.1 (SEM 0.5) mmol.l-1; peak blood glycerol concentration days 5-8: 0.39 (SEM 0.02) mmol.l-1 vs days 19-21: 0.38 (SEM 0.02) mmol.l-1; resting free fatty acids concentration days 5-8: 0.25 (SEM 0.05) mmol.l-1 vs days 19-21: 0.29 (SEM 0.07) mmol.l-1; peak blood glucose concentration days 5-8: 6.7 (SEM 0.5) mmol.l-1 vs days 19-21: 6.6 (SEM 0.2) mmol.l-1; peak capillary blood ammonia concentration days 5-8: 139 (SEM 18.3) mumol.l-1 vs days 19-21: 170 (SEM 18.0) mumol.l-1]. These results suggest neither intermittent high intensity exercise performance nor energy metabolism change between days 5-8 and days 19-21 of a low dosage monophasic OC pill during one pill-cycle.
Lynch
N J
NJ
Scottish School of Sport Studies, University of Strathclyde, 76 Southbrae Drive, Glasgow G13 1PP, Scotland.
De Vito
G
G
Nimmo
M A
MA
D000328:Adult; D001786:Blood Glucose; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D004734:Energy Metabolism / Q000187:drug effects*; D045166:Estradiol Congeners / Q000008:administration & dosage; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D019344:Lactic Acid / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion / Q000187:drug effects*
D001786:Blood Glucose; D003276:Contraceptives, Oral; D045166:Estradiol Congeners; D019344:Lactic Acid; D004997:Ethinyl Estradiol